Search
Nov 25
BridgeBio Founder and CEO Neil Kumar discusses the approval of Attruby and the company's commercialization plans
He describes the label and what he believes it means for the therapy's competitive position. Plus, the commercial plans that have put...
Nov 21, 2023
BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances
Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 in ADH1 and investing in early science.
Apr 27, 2023
BridgeBio's Neil Kumar on drug development
BridgeBio's Neil Kumar shares experiences that may be good learnings for other drug developers and discusses his company's unique model.
.png){kind=logo}
